Coronado: Novel Approach to Bowel Diseases Moves Forward
- Coronado Biosciences (NASDAQ:CNDO) has initiated a Phase 2 trial of Trichuris sues ova (TSO) for the treatment of Crohn’s disease – the treatment is a … Continue Reading
Read nowAuthor Archives: Editorial Staff
Rosetta Genomics Gains after Receiving Entrepreneurial Award
- After receiving a Next Generation Diagnostics Entrepreneurial Company of the Year Award from Frost and Sullivan yesterday, Rosetta Genomics (NASDAQ:ROSG) is up 7% ahead of the … Continue Reading
Read nowExpectations For Profitability, Speculation On Take-Out Driving ELN
Long Ideas - With the bad news on failed Alzheimer’s candidate bapineuzumab out of the way, Elan Corporation, plc (NYSE:ELN) is positioning itself for a brighter future. The … Continue Reading
Read nowSynergy Closing Key Trial; Decision On IRWD's Linaclotide Likely To Have Impact
Long Ideas - Synergy Pharmaceuticals (NASDAQ:SGYP) announced today that its Phase IIb/III trial testing lead drug plecanatide for chronic constipation is fully enrolled. The trial met its 880 … Continue Reading
Read nowArrowhead Direct Offering Has Only Intermittent Effects
- This morning Arrowhead Research (NASDAQ:ARWR) announced a $6.2MM direct offering of common stock and warrants. Shares will be sold to private investors, mostly current shareholders, … Continue Reading
Read nowAmpyra 10mg Beats 5mg, But Weak Overall Results Net Neutral For ACOR
- Acorda Therapeutics (NASDAQ:ACOR) reported this morning that a 5mg dose of Ampyra was not as effective as the approved dose, Ampyra 10mg. The FDA required … Continue Reading
Read nowOrphan Drug PDUFA Extended for NPS Pharmaceuticals
- NPS Pharmaceuticals (NASDAQ:NPSP) announced this morning that the FDA delayed the action date for Gattex, an orphan drug treatment for Short Bowel Syndrome (SBS). The … Continue Reading
Read now